Table 1

Karyotypes and clinical characteristics of dasatinib-treated CML patients with clonal cytogenetic abnormalities in Ph cells

Patient no.*Previous treatmentLength of follow up on dasatinib, moRepresentative karyotype with Ph cloneTime from start of dasatinib to appearance of Ph clone, mDuration of Ph clone, mMDS§Best response on dasatinib, %Karyotype of most recent sampleOutcome
1HU, IFN, IM2347,XY,+8[29]/46,XY,t(9;22) (q34;q11.2)[2]68Trilineage dysplasia746,XY,t(9;22)9q34;q11)[30]A, loss of CyR, AP
2HU, IFN, IM2247,XY,+Y[36]/46,XY[4]715+No046,XY,+Y[3]/46,XY[27]A, CCyR
3HU, IFN, IM2146,XX,ins(22;3)(q11;q26q21) [12]8.512No046,XX,t(9;22)(q34;q11)[30]A, loss of CyR
  • Ph indicates Philadelphia chromosome negative; MDS, myelodysplastic syndrome; HU, hydroxyurea; IFN, interferon alpha; IM, imatinib mesylate; A, Alive; CyR, cytogenetic response; AP, accelerated phase; and CCyR, complete cytogenetic response.

  • * Patients were identified from a series of 35 cases of dasatinib-treated CML. Cytogenetic analysis was carried out on 30 metaphases from each of 151 bone marrow samples, with a median of 4 analyses per patient (range, 1-10). Nineteen patients were in chronic phase, 10 in accelerated phase, and 6 in blast crisis. The median follow-up from start of dasatinib was 16 months (range, 4-23 months). Twenty-seven patients (77%) showed at least a 5% reduction in Philadelphia-positive metaphases over the course of dasatinib treatment, of which 8 patients (23%) demonstrated minimal or minor CyR and 19 patients (54%) showed partial or complete CyR.

  • Karyotype of the sample with the highest level of chromosomally abnormal Ph clone is presented. Ph clone is shown in bold.

  • Calculated as the length of time between the first and last sample with a Ph clone.

  • § Consistent with the World Health Organization Criteria and corresponding with the emergence of the Ph clone.

  • Percentage of Ph-positive cells.

  • The myelodysplastic features observed in patient 1 disappeared at the same time point as the +8 clone, coinciding with loss of CyR.